174 related articles for article (PubMed ID: 16351678)
21. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
22. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
[TBL] [Abstract][Full Text] [Related]
23. Switch strategies in patients on effective HAART.
Maggiolo F; Ripamonti D; Suter F
J Antimicrob Chemother; 2005 Jun; 55(6):821-3. PubMed ID: 15849261
[TBL] [Abstract][Full Text] [Related]
24. Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class.
Hammer SM
Top HIV Med; 2006; 14(4):140-3. PubMed ID: 17114828
[TBL] [Abstract][Full Text] [Related]
25. Thymidine analogue-sparing highly active antiretroviral therapy (HAART).
Nolan D; Mallal S
J HIV Ther; 2003 Feb; 8(1):2-6. PubMed ID: 12840707
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
Gulick R
AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
28. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
Tozzi V; Zaccarelli M; Bonfigli S; Lorenzini P; Liuzzi G; Trotta MP; Forbici F; Gori C; Bertoli A; Bellagamba R; Narciso P; Perno CF; Antinori A;
Antivir Ther; 2006; 11(5):553-60. PubMed ID: 16964822
[TBL] [Abstract][Full Text] [Related]
29. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.
Cihlar T; Ray AS
Antiviral Res; 2010 Jan; 85(1):39-58. PubMed ID: 19887088
[TBL] [Abstract][Full Text] [Related]
30. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
[TBL] [Abstract][Full Text] [Related]
31. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
[TBL] [Abstract][Full Text] [Related]
32. The picture of future therapy.
Gazzard B
Int J Clin Pract Suppl; 1999 Jun; 103():45-8. PubMed ID: 10622045
[TBL] [Abstract][Full Text] [Related]
33. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China.
Liu L; Lu HZ; Henry M; Tamalet C
J Med Virol; 2007 Oct; 79(10):1593-9. PubMed ID: 17705165
[TBL] [Abstract][Full Text] [Related]
34. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Andreoni C; Dori L; Gatti F; Montano M; Buonomini AR; Boldrin C; Palù G; Vullo V; Andreoni M
J Med Virol; 2007 Jul; 79(7):880-6. PubMed ID: 17516532
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
36. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
[TBL] [Abstract][Full Text] [Related]
38. Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.
Golub ET; Benning L; Sharma A; Gandhi M; Cohen MH; Young M; Gange SJ
Clin Infect Dis; 2008 Jan; 46(2):305-12. PubMed ID: 18171267
[TBL] [Abstract][Full Text] [Related]
39. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
[TBL] [Abstract][Full Text] [Related]
40. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004.
Lohse N; Obel N; Kronborg G; Jørgensen LB; Pedersen C; Larsen CS; Kvinesdal B; Sørensen HT; Gerstoft J
Antivir Ther; 2006; 11(5):591-600. PubMed ID: 16964827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
